Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as metformin, sulphonylurea
Avandamet · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| metformin | DRUG | - |
| sulphonylurea | DRUG | - |
| Avandamet | DRUG | - |
Inclusion criteria: * Body mass index \> or = to 25 kg/m2. * HbA1c \> or =7% and \< or =10% at screening. * FPG \> or = 7.0mmol/L (126mg/dL) at visit 2. * Receiving at least 0.85g of metformin at constant dose(s) for at least 8 weeks prior to visit 1a. * Female subjects must be postmenopausal or us...
Avandamet is used for Non-Insulin-Dependent Diabetes Mellitus, also known as type 2 diabetes. It is a small molecule therapy developed by GSK plc for the metabolic therapeutic area. It has been studied in adults with poorly controlled type 2 diabetes.
Avandamet is made by GSK plc, which trades under the ticker GSK. GSK is the developer of this small molecule therapy for Non-Insulin-Dependent Diabetes Mellitus.
Avandamet has been studied in Phase 3 clinical development. One Phase 3 trial has been completed, and no trials are currently active. It is an investigational therapy for Non-Insulin-Dependent Diabetes Mellitus.
Avandamet has been evaluated in the Phase 3 trial NCT00359112, titled AVANDAMET Versus Metformin And Sulphonylurea In People With Poorly Controlled Type 2 Diabetes. This completed trial enrolled 544 participants across Belgium, France, Germany, Ireland, Italy, Lithuania, Mexico, the Netherlands, Spain, Switzerland, and the United Kingdom.
Avandamet is an investigational therapy and has been studied in Phase 3 clinical development for Non-Insulin-Dependent Diabetes Mellitus. It is not described as approved in the available information.